TransMedics Group, Inc. (TMDX) News
Track canonical SquawkNews coverage tagged to TMDX, TransMedics Group, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 24 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TMDX: Sustained 86% CAGR, profitability, and four-pronged growth strategy drive market expansion
Achieved 86% CAGR since FY22, reaching profitability and scaling a multi-organ platform with three FDA-approved products. Four growth initiatives target heart, lung, and kidney markets, EU expansion, and next-gen technol
REGULATION | Sep 15, 2026, 03:10 PM UTC
L
TMDX: Major growth ahead with new transplant tech, European expansion, and strong financial targets
The company highlighted robust growth, advanced technology, and a vertically integrated service model, with major expansion plans in heart, lung, and kidney transplants, and a strategic push into Europe. Long-term financ
NEWS | Sep 15, 2026, 03:00 PM UTC
L
TMDX: Strategic investments and new platforms aim to double market reach and accelerate growth by 2027
The company highlighted robust revenue growth, a unique integrated business model, and strategic investments in heart, lung, and kidney transplant markets. Expansion into Europe and the launch of OCS 3.0 are set to doubl
NEWS | Sep 15, 2026, 02:31 PM UTC
L
TMDX: Plans for rapid transplant volume growth, global expansion, and new organ launches drive outlook
The discussion highlighted ambitious growth targets, with plans to double U.S. NOP cases by 2030, expand internationally, and launch new organ programs, especially kidney. Investments in logistics, automation, and clinic
NEWS | Sep 14, 2026, 08:51 PM UTC
L
TMDX: Transformative growth expected as new organ programs and international expansion accelerate
The discussion highlighted ambitious growth targets, driven by technology innovation, integrated logistics, and a robust pipeline including heart, lung, and kidney programs. Strategic investments in infrastructure and in
NEWS | Sep 14, 2026, 08:25 PM UTC
L
TransMedics appoints Fernando Araujo as CFO
TransMedics appointed Fernando Araujo as chief financial officer and treasurer, effective September 21, 2026. Gerardo Hernandez will transition to an advisory role through April 30, 2027.
EQUITY | Sep 10, 2026, 08:43 PM UTC
L
TransMedics backs FY26 revenue range of $737M-$757M
EARNINGS | Sep 10, 2026, 08:15 PM UTC
M
TransMedics appoints Fernando Araujo CFO effective Sept. 21, 2026
TransMedics appointed Fernando Araujo as Chief Financial Officer, effective September 21, 2026. The company reiterated full-year 2026 revenue guidance of $737 million to $757 million, excluding revenue from its strategic
EARNINGS | Sep 10, 2026, 08:14 PM UTC
L
TransMedics names Fernando Araujo chief financial officer, effective Sept 21
EQUITY | Sep 10, 2026, 08:14 PM UTC
L
TransMedics appoints Fernando Araujo as CFO
TransMedics appointed Fernando Araujo as chief financial officer. The company also reiterated its 2026 financial outlook.
EARNINGS | Sep 10, 2026, 08:05 PM UTC
L
TD Cowen maintains $120 price target on TransMedics shares
TD Cowen maintained a $120.00/share price target on TransMedics Group, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 02:25 PM UTC
L
TransMedics to present at September investor conferences
TransMedics said it will present at upcoming September investor conferences.
EQUITY | Aug 31, 2026, 08:06 PM UTC
L
TMDX - Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
TMDX - Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
EQUITY | Aug 25, 2026, 12:00 PM UTC
L
TMDX - Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
TMDX - Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
EQUITY | Aug 17, 2026, 07:00 AM UTC
H
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Space Exploration Technologies Corp (NASDAQ: SPCX ) fell sharply in pre-market trading after the company
EARNINGS | Aug 05, 2026, 12:03 PM UTC
L
TransMedics Group Raises FY2026 Sales Guidance from $727.000M-$757.000M to $737.000M-$757.000M vs $732.700M Est
TransMedics Group (NASDAQ: TMDX ) raises FY2026 sales outlook from $727.000 million-$757.000 million to $737.000 million-$757.000 million vs $732.700 million estimate.
EARNINGS | Aug 04, 2026, 08:15 PM UTC
L
TMDX TMDX - TransMedics Reports Second Quarter 2026 Financial Results
TMDX TMDX - TransMedics Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:06 PM UTC
H
TMDX PT Cut to $106 at Needham
TMDX price target reduced to $106
EQUITY | Aug 03, 2026, 12:59 PM UTC
L
TMDX - TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
TMDX - TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
EQUITY | Jul 28, 2026, 08:30 PM UTC
L
TMDX Initiated Neutral W/$80.00 PT at UBS
TMDX Initiated Neutral W/$80.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
TMDX Assessing the $2.2B U.S. Kidney Opportunity; Some Questions but a Real Market @ Piper
TMDX Assessing the $2.2B U.S. Kidney Opportunity; Some Questions but a Real Market @ Piper
EQUITY | Jul 22, 2026, 01:13 PM UTC
L
Where Will TransMedics Group Stock Be in 10 Years?
2026-07-03 11:35:00 ET Every year in the United States, roughly 100,000 people sit on transplant waiting lists. Some will wait years. Others won't ma
EQUITY | Jul 03, 2026, 03:42 PM UTC
L
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target
TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ: TMDX ) with a Buy and maintains $120 price target.
EQUITY | Jul 01, 2026, 04:11 PM UTC